Silymarin's Advantage on Graft Effectiveness
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 130 participants.
Also called NCT06801886
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT06801886
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Slovakia
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT06801886. Randomized; single masking; primary purpose prevention. Start 2020-01-07 (actual); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Silymarin's Advantage on Graft Effectiveness
- Acronym
- SAGE
- Condition
- Posttransplant Diabetes Mellitus
- Condition
- Acute Graft Rejection
- Condition
- Biopsy Proven Acute Rejection
- Condition
- Antibody Mediated Rejection of Kidney Transplant
- Condition
- Arterial Hypertension, Chronic Kidney Disease
- Intervention (Drug)
- Silymarine supplementation
- Intervention (Other)
- Placebo Supplementation
- Lead sponsor
- University Hospital, Martin
Record details
- Record id
cardio:ct-nct06801886- Content hash
34fe96a16251a7cefd54a634ef29e49c9b856eac2fd44dd7195bfb1d1173c39f